Two important maternal cardiometabolic disorders (CMDs), hypertensive disorders in
pregnancy (HDP)(including pre-eclampsia) and gestational diabetes mellitus (GDM), result …

Preeclampsia, a hypertensive disorder of pregnancy is estimated to complicate 2%–8% of
pregnancies and remains a principal cause of maternal and fetal morbidity and mortality …

Objective To assess the incidence of hypertensive disorders of pregnancy and related
severe complications, identify other associated factors and compare maternal and perinatal …

This guideline is an evidence based, practical clinical approach to the management of
Hypertensive Disorders of Pregnancy. Since the previous SOMANZ guideline published in …

Pre-eclampsia remains a leading cause of maternal and perinatal mortality and morbidity. It
is a pregnancy-specific disease characterised by de-novo development of concurrent …

Objective This study aimed to review pregnancy hypertension clinical practice guidelines to
inform international clinical practice and research priorities. Study Eligibility Criteria …

Preeclampsia is a potentially serious complication of pregnancy with increasing significance
worldwide. Preeclampsia is the cause of 9%–26% of global maternal mortality and a …

Objective To quantify the risk of future cardiovascular diseases, cancer, and mortality after
pre-eclampsia. Design Systematic review and meta-analysis. Data sources Embase and …

Objective To determine the risk of pre-eclampsia associated with factors that may be present
at antenatal booking. Design Systematic review of controlled studies published 1966-2002 …

OBJECTIVE: The soluble fms-like tyrosine kinase (sFlt-1)/placental growth factor (PlGF) ratio
is a reliable tool in the assessment of preeclampsia. We tested the hypothesis that the sFlt …